Chapter 1. Myelodysplastic Syndrome Market – Scope & Methodology
1.1    Market Segmentation
1.2    Scope, Assumptions & Limitations
1.3    Research Methodology
1.4    Primary Sources
1.5    Secondary Sources 
Chapter 2. Myelodysplastic Syndrome Market – Executive Summary
2.1    Market Size & Forecast – (2024 – 2030) ($M/$Bn)
2.2    Key Trends & Insights
              2.2.1    Demand Side
              2.2.2    Supply Side
2.3    Attractive Investment Propositions
2.4    COVID-19 Impact Analysis 
Chapter 3. Myelodysplastic Syndrome Market – Competition Scenario
3.1    Market Share Analysis & Company Benchmarking
3.2    Competitive Strategy & Development Scenario
3.3    Competitive Pricing Analysis
3.4    Supplier-Distributor Analysis 
Chapter 4. Myelodysplastic Syndrome Market Entry Scenario
4.1    Regulatory Scenario
4.2    Case Studies – Key Start-ups
4.3    Customer Analysis
4.4    PESTLE Analysis
4.5    Porters Five Force Model
              4.5.1    Bargaining Power of Suppliers
              4.5.2    Bargaining Powers of Customers
              4.5.3    Threat of New Entrants
              4.5.4    Rivalry among Existing Players
              4.5.5    Threat of Substitutes 
Chapter 5. Myelodysplastic Syndrome Market – Landscape
5.1    Value Chain Analysis – Key Stakeholders Impact Analysis
5.2    Market Drivers
5.3    Market Restraints/Challenges
5.4    Market Opportunities 
Chapter 6. Myelodysplastic Syndrome Market – By Route of Administration
6.1    Introduction/Key Findings   
6.2    Oral
6.3    Injectables
6.4    Others
6.5    Y-O-Y Growth trend Analysis By Route of Administration
6.6    Absolute $ Opportunity Analysis By Route of Administration, 2024-2030 
Chapter 7. Myelodysplastic Syndrome Market – By Distribution Channel
7.1    Introduction/Key Findings   
7.2    Hospital pharmacies 
7.3    Retail Pharmacies
7.4    Online Pharmacies
7.5    Y-O-Y Growth  trend Analysis By Distribution Channel
7.6    Absolute $ Opportunity Analysis By Distribution Channel, 2024-2030 
Chapter 8. Myelodysplastic Syndrome Market –  By Drug Type
8.1    Introduction/Key Findings   
8.2    Hypomethylating Agents
8.3    Immunomodulatory Drugs
8.4    Anti-anemics
8.5    Y-O-Y Growth trend Analysis By Drug Type
8.6    Absolute $ Opportunity Analysis By Drug Type, 2024-2030 
Chapter 9. Myelodysplastic Syndrome Market , By Geography – Market Size, Forecast, Trends & Insights
9.1    North America
              9.1.1    By Country
                            9.1.1.1    U.S.A.
                            9.1.1.2    Canada
                            9.1.1.3    Mexico
              9.1.2    By Route of Administration
              9.1.3    By Distribution Channel
              9.1.4    By By Drug Type
              9.1.5    Countries & Segments - Market Attractiveness Analysis
9.2    Europe
              9.2.1    By Country
                            9.2.1.1    U.K
                            9.2.1.2    Germany
                            9.2.1.3    France
                            9.2.1.4    Italy
                            9.2.1.5    Spain
                            9.2.1.6    Rest of Europe
              9.2.2    By Route of Administration
              9.2.3    By Distribution Channel
              9.2.4    By Drug Type
              9.2.5    Countries & Segments - Market Attractiveness Analysis
9.3    Asia Pacific
              9.3.1    By Country
                            9.3.1.1    China
                            9.3.1.2    Japan
                            9.3.1.3    South Korea
                            9.3.1.4    India      
                            9.3.1.5    Australia & New Zealand
                            9.3.1.6    Rest of Asia-Pacific
              9.3.2    By Route of Administration
              9.3.3    By Distribution Channel
              9.3.4    By Drug Type
              9.3.5    Countries & Segments - Market Attractiveness Analysis
9.4    South America
              9.4.1    By Country
                            9.4.1.1    Brazil
                            9.4.1.2    Argentina
                            9.4.1.3    Colombia
                            9.4.1.4    Chile
                            9.4.1.5    Rest of South America
              9.4.2    By Route of Administration
              9.4.3    By Distribution Channel
              9.4.4    By Drug Type
              9.4.5    Countries & Segments - Market Attractiveness Analysis
9.5    Middle East & Africa
              9.5.1    By Country
                            9.5.1.1    United Arab Emirates (UAE)
                            9.5.1.2    Saudi Arabia
                            9.5.1.3    Qatar
                            9.5.1.4    Israel
                            9.5.1.5    South Africa
                            9.5.1.6    Nigeria
                            9.5.1.7    Kenya
                            9.5.1.8    Egypt
                            9.5.1.9    Rest of MEA
              9.5.2    By Route of Administration
              9.5.3    By Distribution Channel
              9.5.4    By Drug Type
              9.5.5    Countries & Segments - Market Attractiveness Analysis 
Chapter 10. Myelodysplastic Syndrome Market – Company Profiles – (Overview, Product Portfolio, Financials, Strategies & Developments)
10.1    Bristol-Myers Squibb Company
10.2    Takeda Pharmaceutical Company Limited
10.3    Otsuka Holdings Co., Ltd.
10.4    Lupin,
10.5    Onconova Therapeutics
10.6    Astex Pharmaceutical
10.7    Helsinn Healthcare SA
10.8    Abbott
10.9    Boehringer Ingelheim International GmbH,
10.10    Johnson & Johnson Private Limited.
10.11    MEI Pharma Inc.
10.12    Aprea Therapeutics